Nimotop (Nimodipine)

Nimodipine acts on cerebral vasculature to prevent and treat complications related to reduced blood flow.

• Subarachnoid hemorrhage: reduces the incidence and severity of cerebral vasospasm following bleeding into the subarachnoid space.
• Cerebral ischemia: enhances cerebral perfusion in patients with acute ischemic neurological deficits.
• Neurovascular surgery: supports maintenance of adequate cerebral blood flow during and after operative procedures.

• Nimodipine selectively blocks L‑type calcium channels on vascular smooth muscle, especially in cerebral arteries. This inhibition reduces calcium influx, leading to relaxation of the vascular smooth muscle and consequent vasodilation. The preferential effect on cerebral vessels improves intracranial blood flow without causing marked systemic hypotension, thereby helping to prevent ischemic complications after subarachnoid hemorrhage.

Nimodipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drops in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Flushing: warm sensation and reddening of skin.
• Dizziness: sensation of light‑headedness.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: may require medical intervention.
• Myocardial infarction: rare cardiac ischemic events.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Hepatic enzyme elevation: abnormal liver function tests.
• Thrombocytopenia: reduced platelet count.
• Seizures: uncommon neurologic events.

When using Nimotop, clinicians should consider several safety measures.

• Blood pressure monitoring: observe for hypotension, especially in patients with pre‑existing low pressure.
• Hepatic function: assess liver enzymes before and during therapy.
• Renal impairment: adjust use in patients with severe renal dysfunction.
• Concomitant vasodilators: avoid combining with other potent vasodilators that may amplify hypotensive effects.
• CYP3A4 inhibitors: use caution with strong inhibitors that can increase nimodipine levels.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nimodipine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations.
• Other calcium channel blockers: additive vasodilatory effect leading to severe hypotension.
• Potent vasodilators (e.g., nitroglycerin): risk of profound blood pressure drop.

Moderate Interactions (Monitor Closely)

• Antihypertensives (e.g., ACE inhibitors, beta‑blockers): may enhance blood pressure lowering.
• CYP3A4 substrates (e.g., statins): monitor for increased exposure.
• Diuretics: potential electrolyte disturbances when combined with vasodilation.